Passage Bio Company Top Insiders
PASG Stock | USD 0.43 0.03 6.52% |
Roughly 84 percent of Passage Bio's insiders are selling. The analysis of the overall insider sentiment regarding Passage Bio suggests that a large number of insiders are terrified. Passage Bio employs about 60 people. The company is managed by 13 executives with a total tenure of roughly 140 years, averaging almost 10.0 years of service per executive, having 4.62 employees per reported executive.
Insider Sentiment 16
Mostly Selling
Selling | Buying |
Latest Trades
2025-04-24 | Orbimed Advisors Llc | Disposed 68195 @ 0.32 | View | ||
2025-04-22 | Orbimed Advisors Llc | Disposed 78049 @ 0.34 | View | ||
2025-04-17 | Orbimed Advisors Llc | Disposed 77090 @ 0.33 | View | ||
2025-04-15 | Orbimed Advisors Llc | Disposed 10326 @ 0.38 | View | ||
2025-01-13 | Orbimed Advisors Llc | Disposed 17986 @ 0.64 | View | ||
2025-01-10 | Orbimed Advisors Llc | Disposed 126209 @ 0.66 | View | ||
2025-01-08 | Orbimed Advisors Llc | Disposed 75007 @ 0.68 | View | ||
2025-01-06 | Orbimed Advisors Llc | Disposed 19481 @ 0.77 | View | ||
2024-12-27 | Lynx1 Capital Management Lp | Acquired 373645 @ 0.65 | View | ||
2024-12-20 | Orbimed Advisors Llc | Disposed 230321 @ 0.6 | View | ||
2024-12-11 | Orbimed Advisors Llc | Disposed 80 @ 0.8 | View | ||
2024-12-09 | Orbimed Advisors Llc | Disposed 54181 @ 0.84 | View | ||
2024-12-06 | Orbimed Advisors Llc | Disposed 20903 @ 0.82 | View | ||
2024-12-04 | Orbimed Advisors Llc | Disposed 76200 @ 0.79 | View | ||
2024-11-27 | Lynx1 Capital Management Lp | Acquired 29300 @ 0.67 | View | ||
2024-11-25 | Lynx1 Capital Management Lp | Acquired 259998 @ 0.56 | View | ||
2024-09-18 | Orbimed Advisors Llc | Disposed 25631 @ 0.73 | View | ||
2024-09-16 | Orbimed Advisors Llc | Disposed 63100 @ 0.74 | View |
Monitoring Passage Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. Passage Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.3363) % which means that it has lost $0.3363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8373) %, meaning that it created substantial loss on money invested by shareholders. Passage Bio's management efficiency ratios could be used to measure how well Passage Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.66. The current Return On Capital Employed is estimated to decrease to -0.89. At this time, Passage Bio's Non Current Assets Total are most likely to increase significantly in the upcoming years. The Passage Bio's current Total Current Assets is estimated to increase to about 141.2 M, while Total Assets are projected to decrease to roughly 97.3 M.The current Common Stock Shares Outstanding is estimated to decrease to about 52.1 M. The current Net Loss is estimated to decrease to about (128.6 M)
Passage Bio Workforce Comparison
Passage Bio is regarded fourth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 998. Passage Bio holds roughly 60.0 in number of employees claiming about 6% of equities under Health Care industry.
Passage Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Passage Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Passage Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Passage Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Passage Bio Notable Stakeholders
A Passage Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Passage Bio often face trade-offs trying to please all of them. Passage Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Passage Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
William MD | CEO President | Profile | |
Sue Browne | Senior Development | Profile | |
Simona King | CFO Sec | Profile | |
JD Esq | General Secretary | Profile | |
Gregory Fuest | Vice Marketing | Profile | |
MSc MBA | Chief Officer | Profile | |
Kathleen Borthwick | Principal Finance | Profile | |
Stuart Henderson | Senior Relations | Profile | |
Eden Fucci | Senior Operations | Profile | |
Karl Whitney | Senior Affairs | Profile | |
Mark MD | Chief Officer | Profile | |
David MD | VP Devel | Profile | |
Desiree DDS | VP Affairs | Profile |
About Passage Bio Management Performance
The success or failure of an entity such as Passage Bio often depends on how effective the management is. Passage Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Passage management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Passage management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.63) | (0.66) | |
Return On Capital Employed | (0.85) | (0.89) | |
Return On Assets | (0.63) | (0.66) | |
Return On Equity | (1.06) | (1.00) |
Passage Bio Workforce Analysis
Traditionally, organizations such as Passage Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Passage Bio within its industry.Passage Bio Manpower Efficiency
Return on Passage Bio Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.1M | |
Net Loss Per Executive | 5M | |
Working Capital Per Employee | 990.9K | |
Working Capital Per Executive | 4.6M |
Complementary Tools for Passage Stock analysis
When running Passage Bio's price analysis, check to measure Passage Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Passage Bio is operating at the current time. Most of Passage Bio's value examination focuses on studying past and present price action to predict the probability of Passage Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Passage Bio's price. Additionally, you may evaluate how the addition of Passage Bio to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |